Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Denali Therapeutics Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 209
- +16 vs. Q3 2023
- Shares held
- 115.0M
- +6.57M (+6.1%) vs. Q3 2023
- Total value
- $2.47B
- +$224.9M (+10.0%) vs. Q3 2023
- New holders
- 37
- 71 more added
- Sold out
- 21
- 69 more reduced
2 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital Research Global Investors | 2,909,528 | $62.4M | 0.02% | +29,205+1.0% | Added |
| Takeda Pharmaceutical Co Ltd | 4,214,559 | $86.9M | 26.55% | +4,214,559 | New |
| State Street Corp | 5,485,948 | $117.7M | 0.01% | +1,210,620+28.3% | Added |
| Crestline Management, LP | 5,660,732 | $121.5M | 11.25% | −300,000−5.0% | Reduced |
| Temasek Holdings (Private) Ltd | 6,895,992 | $148.0M | 0.83% | 00.0% | Unchanged |
| Wellington Management Group LLP | 7,274,717 | $156.1M | 0.03% | −14,243−0.2% | Reduced |
| Vanguard Group Inc | 10,834,483 | $232.5M | 0.01% | +236,702+2.2% | Added |
| BlackRock Inc. | 11,543,446 | $247.7M | 0.01% | +658,150+6.0% | Added |
| Baillie Gifford & Co | 14,260,724 | $306.0M | 0.24% | −420,303−2.9% | Reduced |
| Eventide Asset Management, LLC | 0 | $0 | 0.00% | −621,850−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −594,989−100.0% | Sold out |
| Man Group plc | 0 | $0 | 0.00% | – | Sold out |
| TCW Group Inc | 0 | $0 | 0.00% | −141,924−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −118,351−100.0% | Sold out |
| Susquehanna Fundamental Investments, LLC | 0 | $0 | 0.00% | −81,308−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −44,656−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −42,349−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −42,020−100.0% | Sold out |
| Capula Management Ltd | 0 | $0 | 0.00% | −38,720−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −37,404−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −35,800−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −26,618−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −19,787−100.0% | Sold out |
| Gotham Asset Management, LLC | 0 | $0 | 0.00% | −19,391−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −17,381−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −13,942−100.0% | Sold out |
| Teza Capital Management LLC | 0 | $0 | 0.00% | −10,818−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −9,894−100.0% | Sold out |
| Umb Bank N A | 0 | $0 | 0.00% | −306−100.0% | Sold out |
| Tfo-TDC, LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |
| Virginia Retirement Systems Et Al | – | – | – | – | Not filed |